Navigation Links
Study: Modafinil is effective in treating excessive sleepiness
Date:10/15/2007

WESTCHESTER, Ill. A study published in the October 15 issue of the Journal of Clinical Sleep Medicine (JCSM) finds that modafinil is well-tolerated in the treatment of excessive sleepiness associated with disorders of sleep and wakefulness such as shift work sleep disorder, obstructive sleep apnea (OSA) and narcolepsy, and does not affect cardiovascular or sleep parameters.

The study, authored by Thomas Roth, PhD, of the Henry Ford Sleep Center in Detroit, Mich., focused on 1,529 outpatients who received modafinil 200, 300 or 400 mg, or a placebo once per day for up to 12 weeks. A total of 934 patients received modafinil, and 567 received a placebo. The subjects were assessed for adverse events and effects of modafinil on blood pressure/heart rate, electrocardiogram intervals, polysomnography, and clinical laboratory parameters.

According to the results, modafinil was well tolerated versus a placebo, with headache, nausea and infection the most common adverse side effect. The overall incidence of side effects was similar among the three modafinil dosage groups. Adverse events occurring more frequently in the modafinil group than in controls included headache, nausea, dry mouth, anorexia, nervousness, insomnia, anxiety, hypertension and pharyngitis. In patients taking modafinil, 19 serious adverse events occurred, while in the placebo group, there were 10 serious adverse events.

In modafinil-treated patients clinically significant increases in diastolic or systolic blood pressure were infrequent. In the narcolepsy studies one patient in the modafinil group and one in the placebo group had a clinically significant increase in heart rate.

New clinically meaningful electrocardiogram abnormalities were rare with the modafinil and placebo group.

Modafinil did not affect sleep architecture in any patient population according to polysomnography.

Clinically significant abnormalities in mean laboratory parameters were observed in less than one percent of patients in modafinil-treated patients at the final visit.

Modafinil is well tolerated. Furthermore, it appears from these prospective research studies that daily modafinil administration confers a low risk of adverse events or severe adverse events. These results make for a positive risk-benefit ratio for using modafinil to treat excessive sleepiness in patients with shift work sleep disorder, OSA and narcolepsy, said Dr. Roth.

The American Academy of Sleep Medicine (AASM) recommends that people who suspect that they might have a sleep disorder see a primary care physician or a sleep medicine specialist for proper diagnosis and to discuss treatment options before treatment with medications is undertaken.

While modern hypnotics are considered safe, individuals should be aware that, like all medications, side effects may occur in patients.

Sleep medications are effective and safe treatments when used properly and judiciously by a patient who is under the supervision of a sleep medicine or primary care physician.


'/>"/>

Contact: Jim Arcuri
jarcuri@aasmnet.org
708-492-0930
American Academy of Sleep Medicine
Source:Eurekalert

Related medicine news :

1. Counter study: cholesterol drugs no good in preventing colon cancer
2. A strategic study: Soy diet makes heart disease to worsen in male mice
3. Bird Flu Pandemic Study: Clerical & Support Staff May Stay At Home
4. Study: Older Pancreatic Cancer Surgery Survivors Live Long
5. New Study: Pine Bark Significantly Reduces Endometriosis
6. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
7. Inhaled Steroids Safe & Effective for Children with Asthma
8. Morning after pill effective up to five days after having unprotected sex
9. Distraction therapy found very effective in postoperative patients
10. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
11. TELITHROMYCIN - the proven effective new drug for cap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Pixel Film ... users with customizable backdrops in the Christmas edition of the ProDrop series. Pick ... year. Captivate audiences and invoke the spirit of Christmas using ProDrop's wintry generators. ProDrop ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling ... in health and wellness best practices in the past couple of decades, and ... is American Heart Month, which acts as an exceptional opportunity to revise food ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the World Molecular Imaging Congress (WMIC), will be held in New York City, ... is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... to expand dental health services to the developmentally disabled in the Coachella Valley. ... operations to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group ... associations of medical professionals throughout the country. The Guard was specifically designed to ... and procedures, employee training, regulatory updates, and compliance coaching. , In addition to ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016 Brain Cancer patients in ... at West Cancer Center . Optune™, ... inhibit cancer cell replication causing death of cancer cells, ... decade to show a significant extension in overall survival ... Currently, West Cancer Center is the only medical center ...
(Date:2/11/2016)... ROCKLEDGE, Fla. , Feb. 11, 2016 ... have started out 2016 with sales exceeding company targets, ... and have received their trademark from the United States ... Bobby Clark , Chief Executive Officer of PLAD, ... state of Pennsylvania with two ...
(Date:2/11/2016)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... on oncology with an emphasis on the treatment ... engagement of Lars E. Birgerson , M.D., ... Birgerson will provide strategic medical advisory and operational ... help ensure timely facilitation of new clinical trial ...
Breaking Medicine Technology: